Eli Lilly stock price target

What happened: Eli Lilly's stock price has surged to record highs, driven by bullish analyst ratings and price target increases. Leerink analyst David Risinger raised his price target to $1,232 on June 25, citing the company's expanding obesity drug pipeline. Jim Cramer, on multiple occasions, has praised Eli Lilly's CEO and the company's prospects, stating that he can't sell the stock despite its significant run-up. The consensus analyst price target suggests the stock could reach $1,200 by 2026.

Market impact: The pharmaceutical sector, particularly obesity and diabetes drug manufacturers, is affected. Eli Lilly's dominance in these areas is drawing investor attention, with the stock's price-to-earnings multiple below its five-year average, suggesting potential undervaluation. Competitors may face pressure as Eli Lilly continues to gain market share.

What to watch next: Investors should monitor Eli Lilly's upcoming earnings reports, scheduled for July 28 and August 3, for updates on the company's obesity drug pipeline and financial performance. Additionally, the FDA's decision on semaglutide for chronic weight management, expected in the first quarter of 2023, could significantly impact Eli Lilly's stock price.